Glycopyrrolate/formoterol fumarate MDI in mild-to-moderate chronic obstructive pulmonary disease (PIONEER): a protocol for a randomised, double-blind, placebo-controlled trial
Fengyan Wang(First Affiliated Hospital of Guangzhou Medical University), Jia-Xuan Xu(First Affiliated Hospital of Guangzhou Medical University), Yuqi Li(Stanford University), Zhenyu Liang(First Affiliated Hospital of Guangzhou Medical University), Pixin Ran(Guangzhou Experimental Station), Yi Gao(Shenzhen University), Rongchang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College), Zihui Wang(First Affiliated Hospital of Guangzhou Medical University), Dongying Zhang(Huaian First People’s Hospital), Jiang Wu(Xihua University), Yumin Zhou(National Clinical Research Center for Digestive Diseases), Nanshan Zhong(Guangzhou Experimental Station)
Cited by 0
Related Papers
Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study
|The Lancet|2018|1.8k
Prevalence, risk factors, and management of asthma in China: a national cross-sectional study
|The Lancet|2019|773
Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects
|Journal of Clinical Investigation|2005|526
Interfacial engineering to achieve an energy density of over 200 Wh kg−1 in sodium batteries
|Nature Energy|2022|455
Prognostic value of NT-proBNP in patients with severe COVID-19
|Respiratory Research|2020|307